Sugi Predict

Sugi Predict / Compounds / SCHEMBL255156

SCHEMBL255156

SCHEMBL255156

CC(C)(C)OC(=O)N1CCN(c2ccc([N+](=O)[O-])nc2)C(=O)C1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ RAB9A P51151 1/20 0.42
▸ MET P08581 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GPR119 Q8TDV5 2/20 0.41
▸ MEN1 O00255 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ENPP2 Q13822 2/20 0.38
▸ NR1H2 P55055 2/20 0.38
▸ MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29491170 1.00 MAPT (0.51) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL29435691 0.84 MAPT (0.68) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL255485 0.84 MAPT (0.44) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL1392727 0.84 MAPT (0.68) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL29491152 0.84 MAPT (0.44) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL14845641 0.84 MAPT (0.48) MAPTALDH1A1LMNASMN1; SMN2POLB
SCHEMBL162562 0.84 MAPT (0.49) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL29462384 0.83 POLB (0.44) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL22650785 0.83 POLB (0.44) MAPTALDH1A1LMNASMN1; SMN2RAB9A
SCHEMBL26641270 0.83 MAPT (0.70) MAPTALDH1A1LMNASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2026-05-28 — — US disclosed
WO-2025235363-A1 CYCLIN-DEPENDENT KINASE 4 DEGRADERS BLUEPRINT MEDICINES CORPORATION (US) 2025-11-13 — — WO disclosed
US-20240043428-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES ASTEX THERAPEUTICS LTD. (GB) 2024-02-08 — — US disclosed
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 — — US disclosed
CN-110036012-B Pyrido [3,4-d ] pyrimidine derivatives and pharmaceutically acceptable salts thereof 帝人制药株式会社 2022-05-10 — — CN disclosed
CN-114364675-A CDK inhibitors 上海齐鲁锐格医药研发有限公司 2022-04-15 — — CN disclosed
US-11261182-B2 Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof TEIJIN PHARMA LIMITED (JP) 2022-03-01 — — US disclosed
EP-3546456-B1 CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF TEIJIN PHARMA LTD (JP) 2022-01-12 — — EP disclosed
CN-109996800-B Crystal of pyrido [3,4-d ] pyrimidine derivative or solvate thereof 帝人制药株式会社 2021-11-19 — — CN disclosed
US-11174252-B2 Heterocyclic compounds as kinase inhibitors NUVATION BIO INC. (US) 2021-11-16 — — US disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 — — US disclosed
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF Gilead Connecticut INc. (US) 2011-12-08 — — US disclosed
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2011-06-23 — — US disclosed
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2011-06-23 — — US disclosed
EP-2331547-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS Novartis AG (CH) 2011-06-15 — — EP disclosed
WO-2010056875-A1 PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-05-20 — — WO disclosed
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG 2010-04-29 — — US disclosed
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG 2010-04-29 — — US disclosed
WO-2010020675-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS NOVARTIS AG (CH) 2010-02-25 — — WO disclosed
WO-2010020675-A1 PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS NOVARTIS AG (CH) 2010-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301145-A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, LCK MAPT 4467/4885ALDH1A1 3488/4885LMNA 2227/4885
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK9, CDK6, CDK7 MAPT 3344/4885ALDH1A1 3935/4885LMNA 3847/4885
US-11261182-B2 Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof CDK6, CDK4, CDKL4 MAPT 2457/4885ALDH1A1 2897/4885LMNA 1498/4885
US-11174252-B2 Heterocyclic compounds as kinase inhibitors CDK6, CDK4, CDK9 MAPT 3390/4885ALDH1A1 2534/4885LMNA 2478/4885
US-20110152244-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 MAPT 2945/4885ALDH1A1 3688/4885LMNA 4084/4885
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 MAPT 3156/4885ALDH1A1 2992/4885LMNA 3004/4885
US-20240043428-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 MAPT 2945/4885ALDH1A1 3688/4885LMNA 4084/4885
US-20100105653-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK6, CDK8, CDK7 MAPT 2945/4885ALDH1A1 3688/4885LMNA 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.